No more drug shortages. A nonprofit is tackling it head-on. Watch my interview with Martin Van Trieste to find out how they’re making pharma more accessible! buff.ly/O93hclR #drugshortages #medicationaccess #nonprofitpharma #kulkarnilawfirm #klf

Are Your Freebies Legal? Diopsys gave clinics free diagnostic tools. The unintended consequence? More testing, higher Medicare claims—and a federal kickback case. $14.25M later, they’ve paid the price. Know where the legal lines are. Full episode buff.ly/7umX7rA

Is self-reporting your best defense or an open invitation for scrutiny? Darshan and Edye reveal why the current regulatory climate favors transparency but only when handled strategically. Consider whether your SOPs and risk appetite align with the law buff.ly/Vt2c19s

Is Your Pharmacy Ready for the Next Audit? I break down the growing risks pharmacies face when audits strike. Click to learn key strategies and practical tips that will keep your practice compliant, your staff trained, and your license secure. buff.ly/TJVIFW2 #auditrisk

🚨 Novo just pulled the plug on its Hims partnership—just two months in. What happened? I outline the compliance and strategy missteps. Click to read more 👇 #pharmacompliance #telehealthregulations #kulkarnilawfirm #klf

s AI really ready to draft your informed consent forms? Edye and I explore how tools like ChatGPT can speed up first drafts—but also raise serious concerns around IRB templates, OHRP compliance, and patient safety. buff.ly/9EakDVQ #informedconsent #AIinpharma #klf

Could Your DTP Campaigns Be the Next Legal Target? 🎯 A recent court ruling shows how innocent marketing tactics can snowball into serious legal trouble. Watch now to learn how to stay on the right side of the law 👇 #pharmacompliance #directtopatient #kulkarnilawfirm

What does a political healthcare bill have to do with research? More than you’d think. We explain how policy shifts like the Big Beautiful Bill can disrupt clinical trial infrastructure by shrinking site networks and limiting participant coverage.buff.ly/QlFiCMD #klf

Should every site get paid the same in a clinical trial? Watch as Edye Edens and I break down how geography, staffing, and patient access impact site value. Learn how real-world costs clash with one-size-fits-all FMV models. Click here buff.ly/8Nsafpg #klf

If your platform collects health data, you need to hear this. I discuss the wave of legal challenges facing telehealth companies over privacy breaches, pharma partnerships, and advertising risks. Click here to learn more buff.ly/JxGtH1z #pharmamarketing #telehealth #klf

Can non-physicians own clinical trial sites? I break down the complex laws surrounding non-physician ownership in clinical research and explains why it’s crucial to understand the legal implications. Watch now! buff.ly/Al4nfwx #clinicalresearch #researchsites #klf

FMV could be the most misunderstood number in clinical research.We explore how FMV is calculated, who decides the numbers, and why Medicare benchmarks don’t always reflect real-world burdens. Watch to learn what your site or your sponsor might be missing buff.ly/Dlq2efC

Charitable donations by pharma are under scrutiny. Regulators are cracking down on potential kickbacks. Ensuring compliance isn’t just a legal requirement—it’s a necessity for long-term success. Click below for details! buff.ly/tAhyPav #charityfunding #klf

The DOJ has a new target: DEI programs.Companies receiving federal funds are now under pressure to prove their diversity efforts comply with Title VI and Title IX. I explore how to safeguard your policies before investigators show up buff.ly/wokidh2 #DOJenforcement #klf

The clients we’ve served? They’re not just businesses. They’re research sites, sharp consultants, and determined law firms trying to get it right. Edye and I talk about what it means to grow alongside the people you serve. buff.ly/9d8jxdP #lifescienceclients

Your 2025 KOL strategy could backfire—big time. If you’re picking based on name recognition, not trial readiness, you’re inviting scrutiny. Edye and I reveal what regulators really want to see from your expert roster. buff.ly/93nbu9Z #keyopinionleaders #KOLstrategy #klf

Pharma’s most underrated transformation? It wasn’t a blockbuster drug. It was the journey from Direct-to-Consumer to Direct-to-Patient. 💥 Check out the timeline to understand the how—and what’s next 👇 #directtopatient #DTC #pharmamarketing #kulkarnilawfirm #klf

Transferring a medical device? Your checklist better go beyond the obvious. It’s not just about paperwork—it’s about regulatory survival. We’ve flagged 7 essentials that can make or break your transfer. View the infographic before your next move. #medicaldevices #klf

Pharmacy enforcement is heating up! I explain how the Eastern District is using the the False Claims Act to target pharmacies and what steps owners can take to protect themselves. Click below. #pharmacycompliance #falseclaimsact #kulkarnilawfirm #klf

A new telehealth model just got the regulatory go-ahead. Find out how management companies can lease providers and offer backend services without violating kickback laws. I cover the safe harbor framework, FMV rules, and key red flags to avoid. Click below. #telehealth #klf